Eagle Pharma sells Barhemsys (amisulpride) rights in U.S. to LXO Group, Paris, under OTCMKTS: EGRX, effective Jan. 14, 2026.
Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) based in Woodcliff Lake, N.J., disclosed today its decision to divest the marketing authorization for Barhemsys (amisulpride) in the U.S. The Company will transfer this authorization to LXO Group, headquartered in Paris, France. This strategic move signifies Eagle's focus on its core operations and expansion plans. The specifics of the deal, including financial terms and duration, were not publicly disclosed. The transaction is part of Eagle's larger business strategy and marks a significant development for both companies involved.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments